ADAyesha Bharadwaj Das

Ayesha Bharadwaj Das

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ayesha Bharadwaj Das has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intraventricular clindamycin enhances interstitial brain fluid drainage and the blood–brain barrier after a traumatic brain injury

    by Landon S. Ashby, Megan G. Crowe, Daveraj Chakravarty, Sanjeev Medam, Gabriel Frampton, Ayesha B. Das, David A. Hormuth, Thomas E. Yankeelov, Vincent Y. C. Wang, Linda J. Noble-Haeusslein, et al.

    Despite advances in the acute clinical management of severe traumatic brain injuries (TBIs), treating injury-derived secondary pathogenesis remains challenging. We demonstrate intracerebroventricular (I.C.V.) administration of clindamycin alleviates TBI secondary pathogenesis in both focal and diffuse murine models of brain injury. I.C.V. administration of clindamycin increased the motility of ependymal cilia, which line the ventricles and spinal canal, by 30 to 60%, which correlated with interstitial brain fluid drainage through the cortex (r > 0.9 Pearson, n = 4 compounds tested). I.C.V. clindamycin treatment post-TBI also restored the blood–brain barrier (BBB), decreased lesion size, and lowered serum levels of glial fibrillary acidic protein by 2.8-fold. Consistent with these data, a novel objective recognition test revealed an improvement in recognition memory in brain-injured mice treated with clindamycin. These collective findings reveal a counterintuitive finding that I.C.V. clindamycin enhances drainage of toxins from the brain while simultaneously restoring the BBB, potentially providing a new solution for alleviating secondary pathogenesis in brain-injured patients.

  • Open Access

    MRI-Based Blood Clot Phenotyping: An In Vitro Study

    by Grace Nye Bechtel, Ayesha B. Das, Juliette Noyer, Adam M. Bush, David A. Hormuth, Thomas E. Yankeelov, Edward Castillo, Steven Warach, Jan Fuhg, Jonathan I. Tamir, et al.

    Background and Purpose: Neurointerventional outcomes depend on clot composition and may be influenced by clot contraction. Thus, a priori identification of clot composition and contraction could inform procedural strategies and improve outcomes. The goal of our work is to conduct an in vitro test to determine whether MRI can reliably predict both clot composition and contractile state. Materials and Methods: To this end, we prepared blood clots spanning clinically observed compositions (0-80% red blood cells (RBCs)) in both contracted and uncontracted states. Contraction was controlled by coagulating blood with or without thrombin. We imaged these clots using quantitative, clinical, and investigational MRI sequences. Using these data, we then determined whether MRI signal intensities, quantitative parameters, and radiomic features capturing intensity and texture patterns can (i) predict clot hematocrit and (ii) classify clots by composition (RBC-rich vs. fibrin-rich) and contraction state. Results: Quantitative MRI parameters (T1, T2, ADC) decreased with increasing hematocrit (R 2 = 0.56–0.85, p < 0.001), while signal intensities from clinical sequences showed weaker correlations (R 2 = 0.46–0.62, p < 0.001). Radiomic models predicted hematocrit with performance comparable to MRI parameters. When applied to classification, radiomic features accurately discriminated RBC-versus fibrin-rich clots, with AUCs exceeding 0.90 across nearly all sequences. In contrast, classification of contraction state showed greater variability in AUCs across sequences but remained high for quantitative T1 and T2 values (AUCs up to 0.88). Trends were consistent across clots coagulated with and without thrombin. Pooling features across sequences did not outperform the best individual sequence for either regression or classification. Conclusions: We demonstrate that MRI-based radiomic analysis quantitatively characterizes clot composition and contraction in vitro. These findings support the feasibility of using MRI for pre-interventional clot phenotyping, with potential to inform thrombolytic and mechanical thrombectomy strategies. Thus, in vivo studies validating these results are warranted.

  • Open Access

    The ISMRM Open Science Initiative for Perfusion Imaging (OSIPI): Results from the OSIPI–Dynamic Contrast‐Enhanced challenge

    by Eve S. Shalom, Harrison Kim, Rianne A. van der Heijden, Zaki Ahmed, Reyna Patel, David A. Hormuth, Julie C. DiCarlo, Thomas E. Yankeelov, Nicholas J. Sisco, Richard D. Dortch, et al.

    Purpose: has often been proposed as a quantitative imaging biomarker for diagnosis, prognosis, and treatment response assessment for various tumors. None of the many software tools for quantification are standardized. The ISMRM Open Science Initiative for Perfusion Imaging–Dynamic Contrast‐Enhanced (OSIPI‐DCE) challenge was designed to benchmark methods to better help the efforts to standardize measurement.Methods: A framework was created to evaluate values produced by DCE‐MRI analysis pipelines to enable benchmarking. The perfusion MRI community was invited to apply their pipelines for quantification in glioblastoma from clinical and synthetic patients. Submissions were required to include the entrants' values, the applied software, and a standard operating procedure. These were evaluated using the proposed score defined with accuracy, repeatability, and reproducibility components.Results: Across the 10 received submissions, the score ranged from 28% to 78% with a 59% median. The accuracy, repeatability, and reproducibility scores ranged from 0.54 to 0.92, 0.64 to 0.86, and 0.65 to 1.00, respectively (0–1 = lowest–highest). Manual arterial input function selection markedly affected the reproducibility and showed greater variability in analysis than automated methods. Furthermore, provision of a detailed standard operating procedure was critical for higher reproducibility.Conclusions: This study reports results from the OSIPI‐DCE challenge and highlights the high inter‐software variability within estimation, providing a framework for ongoing benchmarking against the scores presented. Through this challenge, the participating teams were ranked based on the performance of their software tools in the particular setting of this challenge. In a real‐world clinical setting, many of these tools may perform differently with different benchmarking methodology.


  • Open Access

    Rapid In Vitro Quantification of a Sensitized Gadolinium Chelate via Photoinduced Triplet Harvesting

    by James A. Tranos, Ayesha Das, Jin Zhang, Sonia Hafeez, Georgios N. Arvanitakis, Stuart A. J. Thomson, Suleiman Khan, Neelam Pandya, Sungheon Gene Kim, Youssef Z. Wadghiri

    Gadolinium (Gd) based contrast agents (GBCAs) are widely used in magnetic resonance imaging (MRI) and are paramount to cancer diagnostics and tumor pharmacokinetic analysis. Accurate quantification of gadolinium concentration is essential to monitoring the biodistribution, clearance, and pharmacodynamics of GBCAs. However, current methods of quantifying gadolinium in blood or plasma (biological media) are both low throughput and clinically unavailable. Here, we have demonstrated the use of a sensitized gadolinium chelate, Gd[DTPA-cs124], as an MRI contrast agent that can be used to measure the concentration of gadolinium via luminescence quantification in biological media following transmetalation with a terbium salt. Gd[DTPA-cs124] was synthesized by conjugating carbostyril-124 (cs124) to diethylenetriaminepentaacetic acid (DTPA) and chelating to gadolinium. We report increases in both stability and relaxivity compared to the clinically approved analog Gd[DTPA] (gadopentetic acid or Magnevist). In vivo MRI experiments were conducted using C57BL6 mice in order to further illustrate the performance of Gd[DTPA-cs124] as an MRI contrast agent in comparison to Magnevist. Our results indicate that similar chemical modification to existing clinically approved GBCA may likewise provide favorable property changes, with the ability to be used in a gadolinium quantification assay. Furthermore, our assay provides a straightforward and high-throughput method of measuring gadolinium in biological media using a standard laboratory plate reader.